Alemtuzumab 30 mg/30mg Solution, 30 mg — NDC 12714-089-30 (Billing 12714-0089-30)
This is a package of 30 mg of Alemtuzumab 30 mg/30mg Solution from Boehringer Ingelheim Pharma GmbH and Co. KG, marketed since May 2001 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 12714-089-30 alone.
- Record
- FDA NDC Directory package listing · Bulk ingredient
- Code segments
- 12714 labeler · 089 product · 30 package
- Package marketed since
- May 7, 2001
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 1271408930 2
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
This is a bulk ingredient listing for alemtuzumab solution, a pharmaceutical substance used by manufacturers and compounding facilities to prepare finished medicines. Alemtuzumab is a monoclonal antibody typically used in medicines designed to treat certain blood cancers and autoimmune conditions by targeting specific immune cells. This listing represents the drug substance itself rather than a finished consumer product ready for patient use.
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Alemtuzumab — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 3, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 12714-0089-30 You're viewing this Main listing | 30 mg in 1 TANK | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Alemtuzumab 30 mg/30mg 12714-0085-30 | Boehringer | 30 mg | — | — | FDA listed | — |
| Alemtuzumab 30 mg/30mgthis 12714-0089-30 | Boehringer | 30 mg | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Boehringer Ingelheim Pharma GmbH and Co. KG labeler code 12714
- Alteplase 50 mg/50mg Powder NDC 12714-082-50
- Alteplase 100 mg/100mg Powder NDC 12714-083-10
- Interferon beta-1b .3 mg/.3mg Powder NDC 12714-084-03
- Alemtuzumab 30 mg/30mg Solution NDC 12714-085-30
- Durvalumab 50 mg/50mg Solution NDC 12714-087-01
- Infliximab 40 mg/40mg Solution NDC 12714-088-40
- Pembrolizumab 25 mg/mL Solution NDC 12714-090-25
- Pembrolizumab 165 mg/mL Liquid NDC 12714-091-99
- Tremelimumab 20 mg/20mg Solution NDC 12714-104-20
- Nerandomilast 9 mg/91 Tablet NDC 12714-122-01
- nerandomilast 18 mg/181 Tablet NDC 12714-123-01
- Zongertinib 60 mg/601 Tablet NDC 12714-128-60
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
About this NDC listing & data coverage
This is a bulk ingredient listing — not a retail prescription package
Alemtuzumab 30 mg/30mg SOLUTION is listed with FDA as a bulk ingredient (a drug substance supplied for further manufacturing or licensed pharmacy compounding). It is not a finished product a patient would receive at a retail pharmacy, so consumer-style information — a patient label, retail pricing, package photos — generally does not exist for this NDC. The listing identifies the substance and package for supply-chain and regulatory purposes.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |